Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease.
about
Acupuncture for multiple sclerosisThe innate immune system in demyelinating diseaseDemyelinating diseasesCo-occurrence of autoimmune thyroid disease in a multiple sclerosis cohort.Virus-mediated autoimmunity in Multiple Sclerosis.The role of EMMPRIN in T cell biology and immunological diseasesCerebral hypoperfusion: a new pathophysiologic concept in multiple sclerosis?Epigenetic Drugs for Multiple SclerosisThe Potential Role of T Helper Cell 22 and IL-22 in Immunopathogenesis of Multiple SclerosisTreatment of autoimmune inflammation by a TLR7 ligand regulating the innate immune systemThe long and evolving relationship between viruses and multiple sclerosisLymphatics in Neurological Disorders: A Neuro-Lympho-Vascular Component of Multiple Sclerosis and Alzheimer's Disease?Gray matters in multiple sclerosis: cognitive impairment and structural MRI.A population-based cohort study suggests an increased risk of multiple sclerosis incidence in patients with type 2 diabetes mellitusUnraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis.Role of the innate immune system in the pathogenesis of multiple sclerosis.Accelerated central nervous system autoimmunity in BAFF-receptor-deficient miceTH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or NatalizumabMale microchimerism in peripheral blood leukocytes from women with multiple sclerosis.Stimulation of adult oligodendrogenesis by myelin-specific T cellsThe risk of fracture in patients with multiple sclerosis: the UK general practice research databaseCodelivery of antigen and an immune cell adhesion inhibitor is necessary for efficacy of soluble antigen arrays in experimental autoimmune encephalomyelitisImmune modulating peptides for the treatment and suppression of multiple sclerosis.Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis.Does helminth activation of toll-like receptors modulate immune response in multiple sclerosis patients?Increased plasma/serum levels of prolactin in multiple sclerosis: a meta-analysis.The role of T cells in cutaneous autoimmune disease.Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors.Cigarette smoking and autoimmune disease: what can we learn from epidemiology?Distinct functions of autoreactive memory and effector CD4+ T cells in experimental autoimmune encephalomyelitis.Presentation and outcomes with clinically apparent interferon beta hepatotoxicity.Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.Systems biology approaches for the study of multiple sclerosis.Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals.Increased IL-23 secretion and altered chemokine production by dendritic cells upon CD46 activation in patients with multiple sclerosis.New insights in the pathogenesis of multiple sclerosis--role of acrolein in neuronal and myelin damage.Membrane bound IL-15 is increased on CD14 monocytes in early stages of MS.CD8(+) T cells in multiple sclerosis.Significant increase in the prevalence of multiple sclerosis in iran in 2011.Toll-like receptors are key players in neurodegeneration.
P2860
Q24241139-7F5F6AAC-F37F-4601-90CB-75AA831946B4Q24597958-15FC181D-9DCA-46B6-BFCA-0F9EADA28DD9Q24676347-9F77B5F1-07CB-4BE8-9217-85A381F3BAB2Q24815557-B7FBC048-5E3E-43B0-B23F-01E7ADCFEF64Q25256901-196EC38A-3772-4387-8DA6-5B36A463E54AQ26998829-EB5C1F1D-ECE7-4E35-A2AE-5DB8F4717717Q27027921-685C238C-1A29-4399-91AA-E488EA6B4EEFQ28076395-12BC9E20-F30C-4096-BA88-709E987FF4E1Q28076400-3A1C334C-EB26-45E0-90B7-62FB5859AE18Q28484146-18552E33-66A2-4D9B-A823-4F0A91CF3D76Q29301310-1630FDD8-1F70-4B22-9EE3-900064C9BDA7Q30275974-B12ED09F-67BD-4200-B774-D11E66EB5021Q30768942-3E65F016-F648-4718-86D2-A65CD167F547Q33571827-A7B5448A-B311-4327-81FB-35DBC63F68F9Q33678267-ABDFB0F6-B1BD-4246-A966-1B8E19BDE25FQ33787624-270E6CC8-D011-4F18-8436-ABF8BEAC0FC4Q34231528-FB92F16A-F30A-4A24-AE22-B790584362F0Q34418098-5A7C65B7-6A0E-4EDE-BCE1-14881976EA7CQ34890939-18FC2BA5-0C8A-4F8E-BAB5-87087C6B379DQ35235842-9C12A71B-BA46-4099-80E4-2F00773BA84BQ35347484-8F1BB66C-ECA7-4D64-8B1D-EE9168A7E520Q35571156-DEE2C5FA-70CC-4324-B0A2-A9AFC0C4640BQ36151968-A53BF54F-F71B-4C78-919A-18276852C629Q36153387-1705B059-F765-45F5-AD2C-0F266DAE09BFQ36186594-75CB9BE9-71E2-484A-877E-E625DBC235EDQ36259406-39F4D5DB-7112-4252-AABE-C077CAED90DAQ36277428-B5606EA8-E285-473D-BCA4-861950B58673Q36593767-F2C56869-5B0A-4B45-A043-A6C26ABE9935Q36677000-73C54A39-067F-473E-B465-F387F19D3D2AQ36778241-34A0DF10-265C-4F12-A945-BCF75A509FFBQ36906633-FEC9C096-ACCA-4FB6-B21D-2F2CDDBD4353Q37122279-78B1DCA4-594A-4D79-AEF6-BF0406422B9FQ37174203-DB993BF7-4EDB-41D7-B41F-565813112585Q37208572-7448D6F4-279D-4EEF-AA00-9223BE9963B5Q37243469-555A926F-65A6-474C-A1F6-8F0C56B5E470Q37291226-D925583E-18C5-46D7-9192-DA8295CDC04AQ37354623-A53077F0-4E07-49B1-9C9F-E14412BAAD5EQ37591260-F41C5EC7-0365-4E4C-ABA2-9351340827E5Q37642258-E7419B09-0E27-4194-A38B-1FD8B41BBE0AQ37880364-2F3E187F-658B-4E87-A3E2-8D8E78B19DBD
P2860
Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease.
@ast
Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease.
@en
type
label
Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease.
@ast
Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease.
@en
prefLabel
Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease.
@ast
Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease.
@en
P1433
P1476
Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease.
@en
P2093
Howard L Weiner
P304
P356
10.1001/ARCHNEUR.61.10.1613
P577
2004-10-01T00:00:00Z